(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Vera Therapeutics's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast VERA's revenue for 2026 to be $3,320,533,573, with the lowest VERA revenue forecast at $914,514,197, and the highest VERA revenue forecast at $5,548,028,867. On average, 13 Wall Street analysts forecast VERA's revenue for 2027 to be $20,421,518,359, with the lowest VERA revenue forecast at $9,731,608,295, and the highest VERA revenue forecast at $38,385,907,914.
In 2028, VERA is forecast to generate $47,019,955,607 in revenue, with the lowest revenue forecast at $26,770,716,218 and the highest revenue forecast at $76,807,707,280.